These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23065626)

  • 1. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.
    Morgans AK; Smith MR; O'Malley AJ; Keating NL
    Cancer; 2013 Feb; 119(4):863-70. PubMed ID: 23065626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
    Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
    JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
    Shahinian VB; Kuo YF
    J Gen Intern Med; 2013 Nov; 28(11):1440-6. PubMed ID: 23670565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
    Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
    BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone complications among prostate cancer survivors: long-term follow-up from the prostate cancer outcomes study.
    Morgans AK; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Penson DF
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):338-42. PubMed ID: 25134939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.
    Suarez-Almazor ME; Peddi P; Luo R; Nguyen HT; Elting LS
    Support Care Cancer; 2014 Feb; 22(2):537-44. PubMed ID: 24146343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate Cancer.
    Hu J; Aprikian AG; Vanhuyse M; Dragomir A
    J Natl Compr Canc Netw; 2020 Oct; 18(10):1374-1381. PubMed ID: 33022649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ; Srinivas S; Perkash I; Terris MK
    Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
    Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
    Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
    Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
    Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.
    Saigal CS; Gore JL; Krupski TL; Hanley J; Schonlau M; Litwin MS;
    Cancer; 2007 Oct; 110(7):1493-500. PubMed ID: 17657815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer.
    Cobran EK; Young HN; Chen RC; Chen X; Reeves J; Godley PA; Shah S
    J Natl Med Assoc; 2019 Jun; 111(3):246-255. PubMed ID: 30389146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.
    Morgans AK; Hancock ML; Barnette KG; Steiner MS; Morton RA; Smith MR
    J Urol; 2012 Mar; 187(3):889-93. PubMed ID: 22245322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.
    Wang C; Raldow AC; Nickols NG; Nguyen PL; Spratt DE; Dess RT; Yu JB; King CR; Chu FI; Chamie K; Litwin MS; Saigal CS; Reiter RE; Liu ST; Rettig MB; Chang AJ; Steinberg ML; Kupelian PA; Kishan AU
    Eur Urol Oncol; 2021 Apr; 4(2):327-330. PubMed ID: 31411981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.
    Kirk PS; Borza T; Shahinian VB; Caram MEV; Makarov DV; Shelton JB; Leppert JT; Blake RM; Davis JA; Hollenbeck BK; Sales A; Skolarus TA
    BJU Int; 2018 Apr; 121(4):558-564. PubMed ID: 29124881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.